Eli Lilly’s lawsuit against Revive Rx accuses the Houston compounding pharmacy of illegally mass-producing copycat versions of Mounjaro and Zepbound and selling them in competition with Lilly’s FDA-approved drugs. Filed in September 2023 in the U.S. District Court for the Southern District of Texas, the case relies on the unfair-competition and consumer-protection statutes of eight states rather than federal trademark law. As of early 2026, most of Lilly’s claims have survived a motion to dismiss and the case is moving into discovery, with no trial date set.1PACER Monitor. Eli Lilly and Company v. Revive RX, LLC
What Eli Lilly Is Accusing Revive Rx of Doing
Revive Rx operates as a licensed 503A compounding pharmacy in Houston. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed pharmacies can compound drugs for individual patients based on a prescription without meeting the FDA’s full manufacturing requirements, so long as they follow certain limits.2FDA. FD&C Act Provisions That Apply to Human Drug Compounding
Lilly’s complaint alleges Revive Rx exploited that exception to churn out large volumes of tirzepatide, the active ingredient in Mounjaro and Zepbound, in direct competition with Lilly’s approved products. Because those compounded drugs never went through the FDA approval process, Lilly says they lack the safety, quality, and effectiveness assurances of the branded versions and put patients at risk.3Caselaw Findlaw. Eli Lilly and Company v. Revive Rx, LLC
The complaint anchors those claims in specific incidents. Revive Rx recalled compounded tirzepatide in May 2023 after products tested as sub-potent.4New York Post. Joe Rogan Guest Brigham Buhler’s ReviveRx Caught Up in Recall In April 2024, the pharmacy recalled 751 vials labeled as tirzepatide (Lot #748127) that actually contained testosterone cypionate. The FDA classified that recall as Class I, its most serious designation, reserved for situations where the product could cause serious injury or death. Patients expecting a diabetes or weight-loss medication received an androgenic hormone instead, with possible consequences including uncontrolled blood sugar for diabetic patients and dangerous effects for people with hormone-sensitive cancers or pregnant women.5The Healthy. Tirzepatide Recall Lilly also cited customer complaints describing Revive Rx’s compounded tirzepatide as “watered-down and ineffective,” along with the pharmacy’s regulatory record for sanitation, sterility, and non-pharmaceutical-grade components.3Caselaw Findlaw. Eli Lilly and Company v. Revive Rx, LLC
Why the Case Is Built on State Law, Not Federal Trademark Claims
Lilly did not sue under the Lanham Act. Instead, the complaint brings unfair-competition claims under the consumer-protection and unfair-trade-practices laws of eight states: Alaska, Colorado, Connecticut, Hawaii, North Carolina, Tennessee, Texas, and Washington.3Caselaw Findlaw. Eli Lilly and Company v. Revive Rx, LLC Each of those statutes, in Lilly’s telling, treats the sale of unapproved copycat drugs as an unfair or deceptive practice actionable by a competitor. That choice of theory shaped everything that followed, because it put front and center the question of whether federal drug law leaves any room for such state-law suits.
The Preemption Detour Through Zyla
Revive Rx moved to dismiss, arguing the FDCA’s compounding framework preempted state-law enforcement by private competitors. Judge Lee H. Rosenthal recognized that the Fifth Circuit was already weighing the same question in a parallel case, Zyla Life Sciences, LLC v. Wells Pharma of Houston, LLC, and on December 27, 2023, stayed the Revive Rx case to wait for that ruling.6GovInfo. Eli Lilly v. Revive Rx, Order Staying Case
On April 10, 2025, the Fifth Circuit reversed the lower court in Zyla, holding that state unfair-competition laws that incorporate or mirror federal FDCA standards are not preempted. When a state statute makes federal law its own, the court reasoned, there is no conflict and therefore no basis for preemption. The panel distinguished Buckman Co. v. Plaintiffs’ Legal Committee, which bars fraud-on-the-FDA claims, saying Buckman does not broadly stop states from regulating conduct also covered by the FDCA. It also rejected the argument that private state-law claims would improperly interfere with FDA enforcement discretion, writing that “the possibility that federal enforcement priorities might be upset is not enough to provide a basis for preemption.”7U.S. Court of Appeals for the Fifth Circuit. Zyla Life Sciences v. Wells Pharma of Houston
That decision removed the biggest obstacle to Lilly’s theory. The Revive Rx case was reinstated in July 2025.3Caselaw Findlaw. Eli Lilly and Company v. Revive Rx, LLC
The December 2025 Ruling on the Motion To Dismiss
On December 15, 2025, Judge Rosenthal issued a memorandum and opinion granting in part and denying in part Revive Rx’s motion to dismiss. The court sorted Lilly’s eight state-law claims into four groups.3Caselaw Findlaw. Eli Lilly and Company v. Revive Rx, LLC
The Texas unfair-competition claim was dismissed with prejudice, meaning Lilly cannot refile it. The Hawaii claim was dismissed without prejudice, leaving Lilly the option to try again. The Alaska and North Carolina claims survived but only conditionally: the court found that both states’ laws contain statutory exemptions that could bar at least part of Lilly’s claims, and ordered Lilly to file an amended complaint alleging specific facts showing why those exemptions do not apply. Claims under the laws of Colorado, Connecticut, Tennessee, and Washington moved forward without qualification, with the court finding Lilly could plausibly prove that Revive Rx violated those states’ unfair-competition statutes by producing compounded versions of Mounjaro and Zepbound.8Bloomberg Law. Judge Trims Lilly Suit Over Mass-Produced Copycat Obesity Drugs
The ruling left the core of the case intact. Lilly lost its home-state Texas claim, but four state-law claims are proceeding and two more remain potentially viable pending the amended complaint. As of early 2026, no trial date has been set, and the case is in discovery and pre-trial motions.3Caselaw Findlaw. Eli Lilly and Company v. Revive Rx, LLC
How the End of the Tirzepatide Shortage Changes the Picture
Much of Revive Rx’s compounding activity took place while tirzepatide was on the FDA’s drug shortage list. Under the FDCA, 503A pharmacies generally cannot compound drugs that are “essentially a copy” of a commercially available product, but that restriction relaxes during a recognized shortage.2FDA. FD&C Act Provisions That Apply to Human Drug Compounding
On December 19, 2024, the FDA declared the tirzepatide shortage resolved, finding manufacturer supply met or exceeded demand.9FDA. FDA Memorandum on Tirzepatide Shortage Resolution The agency gave a short transition window: enforcement discretion for 503A pharmacies ended February 17, 2025, and for 503B outsourcing facilities on March 19, 2025. When the Outsourcing Facilities Association sued to block the change, a judge in the Northern District of Texas in March 2025 denied a preliminary injunction, holding that the FDA did not need to conduct notice-and-comment rulemaking before updating the shortage list.10Wilson Sonsini. FDA Can Keep Tirzepatide Off the Drug Shortage List, Judge Says
Since then, 503A pharmacies can no longer rely on the shortage exception. As of April 2026, the FDA has said it does not intend to take enforcement action against 503A compounders filling four or fewer tirzepatide prescriptions per calendar month. Above that threshold, compounders must show a clinically significant difference from the commercially available drug for an identified patient.11FDA. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize That regulatory change does not resolve Lilly’s suit, which focuses on past conduct, but it forecloses the shortage-based defense going forward.
Where Revive Rx Fits in Lilly’s Broader Campaign
The Revive Rx case was Lilly’s opening move in a wider legal offensive against the compounded-GLP-1 market. By mid-2025, Lilly had also sued Strive Pharmacy, Empower Pharmacy, and four telehealth companies — Mochi Health, Willow Health, Fella Health, and Henry Meds — that allegedly facilitated the sale and prescribing of compounded tirzepatide.12NPR. Eli Lilly Sues Companies Selling Alternative Versions of Its Weight Loss Drug The telehealth complaints add allegations of the unlawful corporate practice of medicine, claiming non-physicians at those companies were improperly influencing prescribing decisions.13Holland & Knight. Eli Lilly Strikes Back Against Pharmacy Compounders and Telehealth Novo Nordisk, which makes the competing GLP-1 drug semaglutide (Ozempic and Wegovy), has run a parallel campaign, with suits against at least 12 defendants by August 2025.14Buchanan Ingersoll & Rooney. Major Update on GLP-1 Litigation Involving Compounding Pharmacies
The financial gap driving these cases is stark. Zepbound carries a list price above $1,000 per month, while compounded tirzepatide has sold for as little as $99.12NPR. Eli Lilly Sues Companies Selling Alternative Versions of Its Weight Loss Drug Because Revive Rx was the first case, its rulings — the Zyla preemption question, and now Judge Rosenthal’s state-by-state parsing of which unfair-competition statutes reach compounding conduct — set the pattern other defendants will confront.